Invesco
XENE icon

Invesco’s Xenon Pharmaceuticals XENE Stock Holding History

Invesco’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.44M Buy
59,103
+8,156
+16% +$376K ﹤0.01% 2326
2025
Q4 		$2.28M Sell
50,947
-5,117
-9% -$215K ﹤0.01% 2561
2025
Q3 		$2.25M Sell
56,064
-3,534
-6% -$124K ﹤0.01% 2571
2025
Q2 		$1.87M Sell
59,598
-146,165
-71% -$4.77M ﹤0.01% 2595
2025
Q1 		$6.9M Sell
205,763
-3,791
-2% -$144K ﹤0.01% 1996
2024
Q4 		$8.21M Sell
209,554
-6,268
-3% -$259K ﹤0.01% 1974
2024
Q3 		$8.5M Sell
215,822
-650,963
-75% -$26.2M ﹤0.01% 1933
2024
Q2 		$33.8M Sell
866,785
-182,741
-17% -$7.3M 0.01% 1177
2024
Q1 		$45.2M Buy
1,049,526
+329,808
+46% +$15.2M 0.01% 1085
2023
Q4 		$33.2M Buy
719,718
+3,415
+0.5% +$121K 0.01% 1188
2023
Q3 		$24.5M Buy
716,303
+16,318
+2% +$610K 0.01% 1249
2023
Q2 		$26.9M Buy
699,985
+683,514
+4,150% +$27.2M 0.01% 1201
2023
Q1 		$589K Buy
+16,471
New +$608K ﹤0.01% 3172
2022
Q2 		– Sell
-198,701
Closed -$6.07M – 4157
2022
Q1 		$6.07M Sell
198,701
-95,399
-32% -$2.86M ﹤0.01% 2276
2021
Q4 		$9.19M Buy
+294,100
New +$8.79M ﹤0.01% 2057
2020
Q1 		– Sell
-12,410
Closed -$163K – 3735
2019
Q4 		$163K Buy
12,410
+1,865
+18% +$19.6K ﹤0.01% 3555
2019
Q3 		$95K Sell
10,545
-3,313
-24% -$31.3K ﹤0.01% 3629
2019
Q2 		$137K Buy
+13,858
New +$133K ﹤0.01% 3657

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco's XENE Position: Q1 2026 in Review

Invesco increased its Xenon Pharmaceuticals (XENE) stake by 16% in Q1 2026, buying an estimated $376K and bringing the position to 59,103 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Invesco first reported a position in XENE in Q2 2019 and has held it in 18 quarters since. The position peaked at $45.2M in Q1 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Invesco held 59,103 shares of Xenon Pharmaceuticals worth $3.44M as of Q1 2026.
  • Invesco bought 8,156 Xenon Pharmaceuticals shares in Q1 2026, an estimated $376K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2326 holding.
  • Invesco first reported a position in Xenon Pharmaceuticals in Q2 2019 and has held it in 18 quarters since.
  • Invesco's Xenon Pharmaceuticals position peaked at $45.2M in Q1 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.